Chimeric Antigen Receptor News and Research

RSS

New base-edited T-cells proven effective to treat lymphoblastic leukemia

Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

15 Jun 2023

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

5 Jun 2023

Novel computational platform can expand the pool of cancer immunotherapy targets

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

17 May 2023

Phase 1 clinical trial of CAR-NKT cell therapy shows promising results in neuroblastoma patients

Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, antitumor activity and immunological characteristics of a genetically engineered natural killer T (NKT) cell immunotherapy for neuroblastoma, a childhood tumor that most commonly arises in the adrenal gland.

15 May 2023

New approach for efficient engineering of cell and gene therapies

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods.

28 Apr 2023

New approach to CAR T-cell therapy shows promise against small cell lung cancer in preclinical study

A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study.

25 Apr 2023

Houston-based cancer survivor donates $10 million to accelerate translational research and clinical trials

Vijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.

20 Apr 2023

Unlocking the potential of RNA lipid nanoparticles to revolutionize cancer treatment

This paper discusses the use of RNA lipid nanoparticles for cancer immunotherapy, which has shown promising results in clinical use. However, only a small percentage of patients respond to existing immunotherapies, and the paper explores opportunities for improvement.

18 Apr 2023

Combination treatment could improve stem cell transplantation process for multiple myeloma patients

The standard treatment for patients with multiple myeloma often includes stem cell transplantation in which the patient's own stem cells are harvested and stored while the patient receives intensive chemotherapy to kill the cancer.

17 Apr 2023

CAR T-cell therapy improves quality of life for patients with blood cancers

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, yet relatively few studies have investigated the impact of the therapy on longitudinal patient quality of life – an aspect of care that often suffers from receiving traditional intensive cancer medications, such as chemotherapy.

30 Mar 2023

The breadth of immune responses following COVID-19 vaccination in hematology patients with diseases and treatments impacting B cell immunity

A study published in Cell Reports Medicine describes that COVID-19 vaccines induce strong T cell response in blood cancer patients, irrespective of antibody response and B cell numbers.

30 Mar 2023

Correcting abnormalities in solid tumor's blood vessels can improve efficacy of CAR-T cell therapy

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited efficacy against glioblastoma-;the deadliest type of primary brain cancer-;and other solid tumors.

14 Mar 2023

AI-assisted analysis helps find new targets for CAR-T cell therapy against acute myeloid leukemia

Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy.

13 Mar 2023

Components of the gut microbiome could be used to better predict efficacy of CAR-T cell therapy

Even though, according to recent preliminary studies, the risk of dying from cancer has declined within the European Union in recent years, cancers remain among the leading causes of death.

13 Mar 2023

Fighting pancreatic cancer with gene and cell biotherapies

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene and cell biotherapies in development to combat pancreatic cancer is published in the peer-reviewed journal Human Gene Therapy.

6 Mar 2023

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

The University of Vermont Cancer Center will offer a novel, highly effective form of cancer treatment called CAR T-cell therapy beginning in February, when final accreditation and approval to begin treating patients is expected.

24 Feb 2023

Personalizing CAR-T cell stimulation during manufacturing can enhance its functionality

New adoptive T cell therapies -; in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, and then infused back into the same patient -; are changing the prospects of cancer patients.

10 Feb 2023

New type of immunotherapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Improving CAR-based-immunotherapies using a molecular anchor

Adding a molecular anchor to the key protein used to recognize cancer in cellular immunotherapies can make the treatments significantly more effective.

3 Feb 2023

CAR T cell therapy may enhance the effectiveness of surgery for solid tumors

CAR T cell therapy, an approach which reprograms patients' own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

11 Jan 2023